Does BRAF V600e mutation predict aggressive features in papillary thyroid cancer? results from four endocrine surgery centers

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 9, 2013, Pages 3702-3712

  Li, Carol ^a   Aragon Han, Patricia ^a   Lee, Kathleen C ^a   Lee, Louis C ^a,c   Fox, Amy C ^e   Beninato, Toni ^g   Thiess, Michele ^b   Dy, Benzon M ^c   Sebo, Thomas J ^d   Thompson, Geoffrey B ^c   Grant, Clive S ^c   Giordano, Thomas J ^f   Gauger, Paul G ^e   Doherty, Gerard M ^e   Fahey Iii, Thomas J ^g   Bishop, Justin ^b   Eshleman, James R ^b   Umbricht, Christopher B ^c   Schneider, Eric B ^a   Zeiger, Martha A ^a  

^a Chief of Endocrine Surgery   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Departments of Surgery   (United States)

^d MAYO CLINIC   (United States)

^e Section of General Surgery   (United States)

^f UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^g WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE;

ADULT; AGE; ARTICLE; BRAF GENE; CANCER CLASSIFICATION; CANCER SIZE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY;

ADULT; AGED; CARCINOMA, PAPILLARY; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PROGNOSIS; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS B-RAF; THYROID NEOPLASMS; THYROIDECTOMY;

EID: 84883691685     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-1584     Document Type: Article

References (43)

1. Enewold L, Zhu K, Ron E, et al. Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980- 2005. Cancer Epidemiol Biomarkers Prev. 2009;18:784-791.
2. Mazzaferri EL. What is the optimal initial treatment of low-risk papillary thyroid cancer (and why is it controversial)? Oncology (Williston Park). 2009;23:579-588.
3. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer; Cooper DS, Doherty GM, Haugen et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167-1214.
4. Scheumann GF, Gimm O, Wegener G, Hundeshagen H, Dralle H. Prognostic significance and surgical management of locoregional lymph node metastases in papillary thyroid cancer. World J Surg. 1994;18:559-567; discussion 567-558.
5. Mazzaferri EL, Kloos RT. Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab. 2001;86:1447-1463.
6. Podnos YD, Smith D, Wagman LD, Ellenhorn JD. The implication of lymph node metastasis on survival in patients with well-differentiated thyroid cancer. Am Surg. 2005;71:731-734.
7. Shimamoto K, Satake H, Sawaki A, Ishigaki T, Funahashi H, Imai T. Preoperative staging of thyroid papillary carcinoma with ultrasonography. Eur J Radiol. 1998;29:4-10.
8. McHenry CR. Prophylactic central compartment neck dissection for papillary thyroid cancer: the search for justification continues. Surgery. 150:1058-1060.
9. Lundgren CI, Hall P, DickmanPW,Zedenius J. Clinically significant prognostic factors for differentiated thyroid carcinoma: a population- based, nested case-control study. Cancer. 2006;106:524-531.
10. Harness JK, Thompson NW, McLeod MK, Pasieka JL, Fukuuchi A. Differentiated thyroid carcinoma in children and adolescents. World J Surg. 1992;16:547-553; discussion 553-544.
11. Noguchi S, Murakami N. The value of lymph-node dissection in patients with differentiated thyroid cancer. Surg Clin North Am. 1987;67:251-261.
12. Noguchi S, Noguchi A, Murakami N. Papillary carcinoma of the thyroid. II. Value of prophylactic lymph node excision. Cancer. 1970;26:1061-1064.
13. Mazzaferri EL, Doherty GM, Steward DL. The pros and cons of prophylactic central compartment lymph node dissection for papillary thyroid carcinoma. Thyroid. 2009;19:683-689.
14. Hughes DT, White ML, Miller BS, Gauger PG, Burney RE, Doherty GM. Influence of prophylactic central lymph node dissection on postoperative thyroglobulin levels and radioiodine treatment in papillary thyroid cancer. Surgery. 148:1100-1106; discussion 1006-1007.
15. Randolph GW. Papillary cancer nodal surgery and the advisability of prophylactic central neck dissection: primum, non nocere. Surgery 148:1108-1112.
16. Pereira JA, Jimeno J, Miquel J, et al. Nodal yield, morbidity, and recurrence after central neck dissection for papillary thyroid carcinoma. Surgery. 2005;138:1095-1100, discussion 1100-1091.
17. Sadowski BM, Snyder SK, Lairmore TC. Routine bilateral central lymph node clearance for papillary thyroid cancer. Surgery. 2009; 146:696-703; discussion 703-695.
18. Giles Senyurek Y, Tunca F, Boztepe H, Alagol F, Terzioglu T, Tezelman S. The long term outcome of papillary thyroid carcinoma patients without primary central lymph node dissection: expected improvement of routine dissection. Surgery. 2009;146:1188-1195.
19. Goutas N, Vlachodimitropoulos D, Bouka M, Lazaris AC, Nasioulas G, Gazouli M. BRAF and K-RAS mutation in a Greek papillary and medullary thyroid carcinoma cohort. Anticancer Res. 2008;28: 305-308.
20. Kim SK, Song KH, Lim SD, et al. Clinical and pathological features and the BRAF(V600E) mutation in patients with papillary thyroid carcinoma with and without concurrent Hashimoto thyroiditis. Thyroid. 2009;19:137-141.
21. Li C, Lee KC, Schneider EB, ZeigerMA.BRAFV600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-A nalysis. J Clin Endocrinol Metab. 97:4559-4570.
22. Xing M. Prognostic utility of BRAF mutation in papillary thyroid cancer. Mol Cell Endocrinol. 321:86-93.
23. Adeniran AJ, Zhu Z, Gandhi M, et al. Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol. 2006;30:216-222.
24. Basolo F, Torregrossa L, Giannini R, et al. Correlation between the BRAF V600E mutation and tumor invasiveness in papillary thyroid carcinomas smaller than 20 millimeters: analysis of 1060 cases. J Clin Endocrinol Metab. 2010;95:4197-4205.
25. Frasca F, Nucera C, Pellegriti G, et al. BRAF(V600E) mutation and the biology of papillary thyroid cancer. Endocr Relat Cancer. 2008; 15:191-205.
26. Guan H, Ji M, Bao R, et al. Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer. J Clin Endocrinol Metab. 2009;94:1612-1617.
27. Kim J, Giuliano AE, Turner RR, et al. Lymphatic mapping establishes the role of BRAF gene mutation in papillary thyroid carcinoma. Ann Surg. 2006;244:799-804.
28. Fugazzola L, Mannavola D, Cirello V, et al. BRAF mutations in an Italian cohort of thyroid cancers. Clin Endocrinol (Oxf)). 2004;61: 239-243.
29. Ito Y, Yoshida H, Maruo R, et al. BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients. Endocr J. 2009;56:89-97.
30. So YK, Son YI, Park JY, Baek CH, Jeong HS, Chung MK. Preoperative BRAF mutation has different predictive values for lymph node metastasis according to tumor size. Otolaryngol Head Neck Surg. 145:422-427.
31. Lee X, Gao M, Ji Y, et al. Analysis of differential BRAF(V600E) mutational status in high aggressive papillary thyroid microcarcinoma. Ann Surg Oncol. 2009;16:240-245.
32. Xing M, Clark D, Guan H, et al. BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer. J Clin Oncol. 2009;27:2977-2982.
33. Yip L, Nikiforova MN, Carty SE, et al. Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation. Surgery. 2009;146:1215-1223.
34. Chen G, Olson MT, O'Neill A, et al. A virtual pyrogram generator to resolve complex pyrosequencing results. J Mol Diagn. 2012;14: 149-159.
35. Lee KC, Li C, Schneider EB, et al. Is BRAF mutation associated with lymph node metastasis in patients with papillary thyroid cancer? Surgery. 2012;152:977-983.
36. Elsheikh TM, Asa SL, Chan JK, et al. Interobserver and intraobserver variation among experts in the diagnosis of thyroid follicular lesions with borderline nuclear features of papillary carcinoma. Am J Clin Pathol. 2008;130:736-744.
37. Renshaw AA, Gould EW. Why there is the tendency to " overdiagnose" the follicular variant of papillary thyroid carcinoma. Am J Clin Pathol. 2002;117:19-21.
38. Borson-Chazot F, Causeret S, Lifante JC, Augros M, Berger N, Peix JL. Predictive factors for recurrence from a series of 74 children and adolescents with differentiated thyroid cancer. World J Surg. 2004; 28:1088-1092.
39. Haveman JW, van Tol KM, Rouwé CW, Piers DA, Plukker JT. Surgical experience in children with differentiated thyroid carcinoma. Ann Surg Oncol. 2003;10:15-20.
40. Popovtzer A, Shpitzer T, Bahar G, Feinmesser R, Segal K. Thyroid cancer in children: management and outcome experience of a referral center. Otolaryngol Head Neck Surg. 2006;135:581-584.
41. La Quaglia MP, Black T, Holcomb GW 3rd, et al. Differentiated thyroid cancer: clinical characteristics, treatment, and outcome in patients under 21 years of age who present with distant metastases. A report from the Surgical Discipline Committee of the Children's Cancer Group. J Pediatr Surg. 2000;35:955-959; discussion 960.
42. Randolph GW, Duh QY, Heller KS, et al. The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension. Thyroid. 2012;22: 1144-1152.
43. XingM,Alzahrani AS, Carson KA, et al. Association betweenBRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA. 2013;309:1493-1501.